Center for Thrombosis and Hemostasis (CTH)

Welcome to the website of the CTH!

CTH-Logo_ENG-spons_transparent.png

The Center for Thrombosis and Hemostasis Mainz (CTH) was established in 2010 as an Integrated Research and Treatment Center (IFB) funded by the German Ministry for Education and Research (BMBF). The CTH provides a unique interdisciplinary environment that facilitates basic research, innovative patient care and the development of new diagnostic approaches and therapies. The CTH fosters translational research from bedside-to-bench and vice versa in the field of thrombosis and hemostasis and career development of physician scientists and biomedical researchers.

 

On behalf of the CTH, we invite you to inform yourself about the different tasks and projects.


Yours

Professor Stavros Konstantinides, MD (Medical Director CTH)

Professor Wolfram Ruf, MD (Scientific Director CTH)

Dr. Jana Grünewald (General Manager CTH)

 

 

Gesch_Dir_Jana.jpg

Executive Directors (f.l.t.r. Prof. Ruf, Prof. Konstantinides, Dr. Grünewald)

Print
Last Update: Feb 14, 2023
Information about the CTH

Job advertisements

Press release

Links

EU-HORIZON research project SERENITY

For the EU-HORIZON research project SERENITY – "Towards Cancer Patient Empowerment for Optimal Use of Antithrombotic Therapy at the End of Life" – we are looking for physicians who are involved in the care of cancer patients and are interested in a survey on antithrombotic therapy in the end-of-life care of cancer patients.

For more information please click here.

curATime funded by the Federal Ministry of Education and Research (BMBF)

curATime - "Cluster for Atherothrombosis and Individualized Medicine" - jointly developed by TRON gGmbH, Mainz University Medical Center and the German Research Center for Artificial Intelligence (DFKI) is now one of the clusters of the "Clusters4Future" initiative of the German Federal Ministry of Education and Research (BMBF). For the first, three-year implementation phase, curATime will receive funding totaling 15 million euros. (July 2022) Press release.